Musculoskeletal · PANCE / PANRE

Polymyalgia Rheumatica (PMR)

Inflammatory syndrome of shoulder and hip girdle stiffness in adults over 50; dramatic response to low-dose steroids.

Also known as: PMR, polymyalgia

Overview

Inflammatory syndrome of older adults characterized by bilateral aching and morning stiffness of the shoulder and pelvic girdle, markedly elevated inflammatory markers, and rapid response to low-dose corticosteroids. Closely related to giant cell arteritis.

Epidemiology

Almost exclusively in adults over 50; peak incidence 70-80. Female predominance 2-3:1. More common in people of Northern European ancestry. About 15-20% of PMR patients develop GCA, and about 40-50% of GCA patients have PMR features.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Polymyalgia Rheumatica (PMR) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Age >50 (essentially required)
  • Female sex
  • Northern European ancestry
  • HLA-DR4 association
  • Coexisting or prior giant cell arteritis

Pathophysiology

Subclinical large-vessel and bursal inflammation driven by IL-6 and innate immune activation. Subdeltoid bursitis, biceps tenosynovitis, and hip trochanteric bursitis underlie the proximal stiffness rather than primary muscle disease.

Clinical presentation

Symptoms

  • Subacute onset of bilateral shoulder and hip girdle aching and stiffness
  • Morning stiffness >45 minutes (often hours)
  • Difficulty rising from a chair or lifting arms above the head
  • Constitutional symptoms in 30-50%: fatigue, low-grade fever, anorexia, weight loss
  • No true muscle weakness once pain is controlled

Signs / physical exam

  • Restricted active shoulder and hip motion limited by pain, not weakness
  • Tenderness over deltoids, trapezii, trochanters
  • Normal muscle strength on confrontation testing
  • Screen carefully for GCA features: temporal artery tenderness, jaw claudication, scalp tenderness, visual symptoms

Differential diagnosis

  • Giant cell arteritis — Headache, scalp tenderness, jaw claudication, vision changes; coexists with PMR — always screen for cranial symptoms
  • Rheumatoid arthritis (elderly-onset) — Symmetric small-joint synovitis, RF/CCP positive, erosions on imaging; may overlap clinically
  • Inflammatory myopathy (polymyositis, dermatomyositis) — True muscle weakness, elevated CK, EMG/biopsy changes
  • Hypothyroidism — Proximal stiffness, elevated CK, low TSH/T4
  • Statin myopathy — Recent statin use, elevated CK, weakness more than stiffness
  • Fibromyalgia — Diffuse pain, normal ESR/CRP, age usually <60
  • Paraneoplastic / lymphoma — Atypical features, poor or delayed steroid response, weight loss; pursue malignancy workup if response inadequate
  • Osteoarthritis of shoulders/hips — Mechanical pain, normal inflammatory markers, no constitutional symptoms

Diagnostic workup

Diagnostic criteria

2012 EULAR/ACR provisional criteria: age ≥50, bilateral shoulder pain, abnormal CRP or ESR, plus weighted morning stiffness, hip involvement, absence of other joint pain, and absence of RF/anti-CCP.

Labs

  • ESR — characteristically >40 mm/h (often >50-100); CRP elevated and may be more sensitive
  • CBC — normochromic normocytic anemia, thrombocytosis
  • CK — normal (excludes inflammatory myopathy)
  • TSH (exclude hypothyroidism)
  • RF, anti-CCP, ANA — usually negative; help exclude RA and SLE
  • Comprehensive metabolic panel (baseline before steroids)

Imaging

  • Shoulder ultrasound or MRI — subacromial-subdeltoid bursitis, biceps tenosynovitis, glenohumeral synovitis (supportive but not required)
  • Temporal artery ultrasound or biopsy if GCA features develop
  • PET-CT in atypical cases — can show large-vessel uptake

Diagnostic algorithm

FeaturePMRGiant Cell Arteritis
Age>50>50
Key symptomsShoulder/hip stiffness, morning stiffness >45 minNew headache, jaw claudication, scalp tenderness, visual loss
ESR/CRPMarkedly elevatedMarkedly elevated
ImagingBursitis on US/MRITemporal artery US (halo) or biopsy
Initial steroid dosePrednisone 12.5-25 mg/dayPrednisone 40-60 mg/day (or 1 g IV pulse if vision threat)
Overlap15-20% develop GCA40-50% have PMR features
PMR vs GCA — overlapping spectrum, very different steroid doses.

Treatment

First-line

  • Prednisone 12.5-25 mg/day — dramatic improvement within 48-72 hours is both therapeutic and diagnostic
  • Slow taper over 1-2 years guided by symptoms and inflammatory markers (typical schedule: reduce by 2.5 mg every 2-4 weeks until 10 mg, then 1 mg every 1-2 months)
  • Bone-protective therapy: calcium 1000-1200 mg/day, vitamin D 800-2000 IU/day, plus bisphosphonate if at risk (almost all elderly patients on chronic steroids qualify)
  • PPI for GI protection if NSAIDs or anticoagulants coadministered

Complications

  • Relapse during taper (very common — usually managed with small dose increases)
  • Steroid-related: osteoporosis, hyperglycemia/diabetes, hypertension, weight gain, cataracts, infection, adrenal insufficiency
  • Progression to or unmasking of giant cell arteritis
  • Misdiagnosis: occult RA, malignancy, or polymyositis

PANCE pearls

  • A truly dramatic response to 15-20 mg of prednisone within 72 hours is one of the most useful clinical signs in rheumatology.
  • Always screen for GCA at every PMR visit — sudden vision loss is a preventable catastrophe.
  • Normal CK separates PMR from inflammatory myopathies.
  • Failure to taper below 10 mg or atypical features should prompt reconsideration of the diagnosis.

References

  • EULAR/ACR 2012 — 2012 Provisional Classification Criteria for PMR (Dasgupta et al., Ann Rheum Dis 2012)
  • EULAR/ACR 2015 — 2015 Recommendations for the Management of PMR (Dejaco et al., Ann Rheum Dis 2015)

Practice Musculoskeletal questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.